EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Transferrin-Conjugated, Camptothecin-Bearing Dendrimersomes Entrapping Docetaxel as a Dual-Drug Nanoplatform for Targeted Prostate Cancer Therapy

Musa Albatsh iD, Zainab Al-Quraishi iD, Partha Laskar, Sukrut Somani, Craig Irving, Graeme R Mackenzie, Stuart Woods iD, Craig W Roberts iD, Margaret Mullin, Christine Dufès iD

Pharmaceutics · 04.08.2026 · 18 (8) · 959

DOI: 10.3390/pharmaceutics18080959 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 04.08.2026. Verfasst von Musa Albatsh und 9 weiteren Autor:innen. Beteiligte Einrichtung: Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 161 Cathedral Street, Glasgow G4 0RE, UK. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Middle East University, University of Strathclyde, Worldwide Cancer Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Advanced prostate cancer remains difficult to treat because docetaxel, although clinically important, is limited by systemic toxicity, poor tumor selectivity, and acquired resistance. Camptothecin is a potent anticancer agent, but its clinical application is restricted by poor solubility and instability. This study investigated the synergy between docetaxel and camptothecin and developed transferrin-conjugated, camptothecin-bearing dendrimersomes entrapping docetaxel as a targeted nanocarrier for prostate cancer therapy.

Methods

Drug synergy was evaluated in PC3-Luc cells using an MTT assay and combination index analysis. Transferrin-conjugated, disulfide-linked camptothecin-bearing PEGylated DAB dendrimers were synthesized and characterized by 1H-NMR, critical aggregation concentration analysis, transmission electron microscopy, and entrapment efficiency measurements. pH- and redox-dependent drug release was assessed by dialysis. Cellular uptake and uptake mechanisms were investigated by confocal microscopy, flow cytometry, and inhibitor studies in PC3-Luc, DU145, and LNCaP cells. Anti-proliferative efficacy was determined by an MTT assay.

Results

Docetaxel and camptothecin showed marked synergy in PC3-Luc cells, with a minimum combination index of 0.20 ± 0.01 and 88.10 ± 0.41% growth inhibition at low nanomolar concentrations. Transferrin-conjugated dendrimersomes self-assembled into spherical vesicles with a critical aggregation concentration of approximately 250 µg/mL. They had high docetaxel entrapment efficiency (89.10 ± 0.08%) and enhanced drug release under acidic and reductive conditions. They significantly increased cellular uptake of docetaxel relative to non-targeted dendrimersomes (by up to 3-fold) and free drugs (by up to 20-fold), mainly through transferrin receptor-mediated endocytosis, and improved anti-proliferative activity in all three cell lines. Tf-conjugated DPSSC produced the lowest IC50 values among the tested formulations: 11.72 ± 1.02 nM in PC3-Luc, 9.88 ± 1.22 nM in DU145, and 7.88 ± 1.35 nM in LNCaP cells.

Conclusions

Transferrin-conjugated camptothecin-based dendrimersomes entrapping docetaxel represent a promising multifunctional nanocarrier for prostate cancer that combines synergistic dual-drug therapy, active targeting, and stimulus-responsive release, supporting further evaluation as a selective delivery strategy in advanced prostate cancer using preclinical models and in vivo studies.

Schlagwörter

Stichwörter der Autor:innen

camptothecincancer therapycellular uptakedendrimerdendrimersomedocetaxelprostate cancertransferrin

Autor:innen und Institutionen

  • Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 161 Cathedral Street, Glasgow G4 0RE, UK.
  • Faculty of Pharmacy, Middle East University, Queen Aliaa Airport Street, Amman 11610, Jordan.
  • Department of Chemistry, School of Science, Gandhi Institute of Technology and Management, Visakhapatnam 530045, India.
  • Department of Pure and Applied Chemistry, University of Strathclyde, 295 Cathedral Street, Glasgow G1 1XL, UK.
  • School of Health and Life Sciences, University of the West of Scotland, Paisley Campus, High Street, Paisley PA1 2BE, UK.
  • Cell Analysis Facility, Medical and Veterinary & Life Sciences Shared Research Facilities, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8QQ, UK.

ORCID-Profile: Musa Albatsh, Zainab Al-Quraishi, Stuart Woods, Craig W Roberts, Christine Dufès

Förderung

  • Middle East University
  • University of Strathclyde
  • Worldwide Cancer Research
  • Vivensa Foundation
  • Dunhill Medical Trust

Zitieren

APA

Albatsh, M., Al-Quraishi, Z., Laskar, P., Somani, S., Irving, C., Mackenzie, G. R., Woods, S., Roberts, C. W., Mullin, M., & Dufès, C. (2026). Transferrin-Conjugated, Camptothecin-Bearing Dendrimersomes Entrapping Docetaxel as a Dual-Drug Nanoplatform for Targeted Prostate Cancer Therapy. Pharmaceutics, 18(8), 959. https://doi.org/10.3390/pharmaceutics18080959

Vancouver

Albatsh M, Al-Quraishi Z, Laskar P, Somani S, Irving C, Mackenzie GR, et al. Transferrin-Conjugated, Camptothecin-Bearing Dendrimersomes Entrapping Docetaxel as a Dual-Drug Nanoplatform for Targeted Prostate Cancer Therapy. Pharmaceutics. 2026;18(8):959. doi:10.3390/pharmaceutics18080959

BibTeX
@article{Albatsh2026,
  author = {Albatsh, Musa and Al-Quraishi, Zainab and Laskar, Partha and Somani, Sukrut and Irving, Craig and Mackenzie, Graeme R and Woods, Stuart and Roberts, Craig W and Mullin, Margaret and Dufès, Christine},
  title = {Transferrin-Conjugated, Camptothecin-Bearing Dendrimersomes Entrapping Docetaxel as a Dual-Drug Nanoplatform for Targeted Prostate Cancer Therapy},
  journal = {Pharmaceutics},
  year = {2026},
  volume = {18},
  number = {8},
  pages = {959},
  doi = {10.3390/pharmaceutics18080959}
}
Kostenlos starten →